首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL13 |
| Uniprot No | Q53X90 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-109aa |
| 氨基酸序列 | VLEVYYTSLRCRCVQESSVFIPRRFIDRIQILPRGNGCPRKEIIVWKKNK SIVCVDPQAEWIQRMMEVLRKRSSSTLPVPVFKRKIP |
| 预测分子量 | 10 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL13重组蛋白的3篇代表性文献的简要整理(注：文献信息基于公开研究归纳，非真实引用)：
---
1. **标题**：*CXCL13 regulates B cell recruitment and positioning in lymphoid tissues*
**作者**：Smith A, et al.
**摘要**：研究利用重组CXCL13蛋白在小鼠模型中证实其通过结合CXCR5受体介导B细胞定向迁移，促进次级淋巴器官中滤泡结构的形成。
2. **标题**：*Recombinant CXCL13 exacerbates autoimmune arthritis by promoting germinal center formation*
**作者**：Li Y, et al.
**摘要**：通过注射重组CXCL13蛋白，揭示其在类风湿性关节炎模型中增强生发中心反应和自身抗体产生，提示其作为治疗靶点的潜力。
3. **标题**：*Structural characterization of CXCL13 and its interaction with glycosaminoglycans*
**作者**：Wang H, et al.
**摘要**：通过重组蛋白的晶体结构解析，阐明CXCL13与细胞表面糖胺聚糖的结合模式，为设计抑制其功能的分子提供结构基础。
---
如需具体文献，建议在PubMed或Sci-Hub中检索关键词“CXCL13 recombinant protein”获取原文。
CXCL13. also known as B lymphocyte chemoattractant (BLC) or B cell-attracting chemokine 1 (BCA-1), is a small chemokine protein belonging to the CXC subfamily. It plays a critical role in immune regulation by selectively recruiting B lymphocytes and follicular helper T cells (Tfh) through interaction with its receptor CXCR5. This chemokine is essential for the formation of secondary lymphoid tissues, including lymph nodes and Peyer’s patches, and facilitates the organization of germinal centers during adaptive immune responses. Structurally, CXCL13 contains conserved cysteine residues typical of CXC chemokines, with its N-terminal region crucial for receptor binding and activation.
Recombinant CXCL13 protein is produced using genetic engineering techniques, often expressed in systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. It is widely used in research to study immune cell migration, lymphoid neogenesis, and inflammatory processes. In disease contexts, CXCL13 overexpression has been linked to autoimmune disorders (e.g., rheumatoid arthritis, lupus), B cell malignancies (e.g., lymphoma), and neuroinflammatory conditions like multiple sclerosis. Its levels in cerebrospinal fluid are increasingly recognized as a biomarker for neuroinflammation.
Pharmaceutically, recombinant CXCL13 aids in drug discovery targeting CXCR5 signaling pathways. Inhibitors of this axis are being explored for treating autoimmune diseases and cancer. The protein’s activity is typically validated using chemotaxis assays, receptor-binding studies, and functional tests in immune cell models. Its production requires stringent quality controls to confirm bioactivity, endotoxin levels, and purity, ensuring reliability for both experimental and therapeutic applications.
×
